For the better part of two decades, the pharmacological landscape for Attention-Deficit/Hyperactivity Disorder (ADHD) felt like a perpetual exercise in recycling. Pharmaceutical companies routinely packaged the same tried-and-true molecules—primarily methylphenidate and various amphetamine salts—into increasingly sophisticated delivery systems. We saw extended-release capsules, osmotic pumps, chewable tablets, and sprinkle formulations. Yet, beneath the innovative packaging, the…